Corindus Vascular Robotics Inc. (NYSEMKT:CVRS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Wednesday.

According to Zacks, “Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company’s product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts. “

Shares of Corindus Vascular Robotics (NYSEMKT:CVRS) remained flat at $1.17 during mid-day trading on Wednesday. 78,773 shares of the company were exchanged. Corindus Vascular Robotics has a 12 month low of $0.73 and a 12 month high of $3.79. The firm’s market capitalization is $139.16 million. The stock has a 50-day moving average of $1.30 and a 200 day moving average of $1.24.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/corindus-vascular-robotics-inc-cvrs-rating-increased-to-hold-at-zacks-investment-research.html

Corindus Vascular Robotics (NYSEMKT:CVRS) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.06) by $0.01. Equities analysts anticipate that Corindus Vascular Robotics will post ($0.25) EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in the company. State Street Corp boosted its position in Corindus Vascular Robotics by 12.3% in the second quarter. State Street Corp now owns 258,877 shares of the company’s stock valued at $369,000 after buying an additional 28,377 shares during the period. Bank of New York Mellon Corp boosted its position in Corindus Vascular Robotics by 44.4% in the second quarter. Bank of New York Mellon Corp now owns 164,570 shares of the company’s stock valued at $235,000 after buying an additional 50,636 shares during the period. GAM Holding AG boosted its position in Corindus Vascular Robotics by 5.7% in the second quarter. GAM Holding AG now owns 1,060,920 shares of the company’s stock valued at $1,522,000 after buying an additional 57,239 shares during the period. Schwab Charles Investment Management Inc. boosted its position in Corindus Vascular Robotics by 236.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 84,000 shares of the company’s stock valued at $121,000 after buying an additional 59,000 shares during the period. Finally, California State Teachers Retirement System boosted its position in Corindus Vascular Robotics by 139.3% in the second quarter. California State Teachers Retirement System now owns 115,258 shares of the company’s stock valued at $165,000 after buying an additional 67,091 shares during the period.

Corindus Vascular Robotics Company Profile

Corindus Vascular Robotics, Inc designs, manufactures and sells precision vascular robotic-assisted systems for use in interventional vascular procedures (the CorPath System). The Company operates through the development, marketing and sales of robotic-assisted vascular interventions segment. The Company’s product, the CorPath 200 System, is a vascular robotic system, which is engaged in stent placement in percutaneous coronary intervention (PCI) procedures.

Get a free copy of the Zacks research report on Corindus Vascular Robotics (CVRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Corindus Vascular Robotics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.